Podcast Interview: Harvey Berger, CEO, ARIAD Pharmaceuticals

Jun 30, 0011
By Pharmaceutical Executive Editors

Interview: Harvey Berger

Harvey Berger, CEO at ARIAD Pharmaceuticals, discusses his deal with Merck on riduforolimus, a cancer drug in Phase 3, and ARIAD's commercialization strategy going forward.

native1_300x100
lorem ipsum